VLA
Click for more information
0.00% $1.75 viralytics limited

Another example showing the ridiculous price we are being...

  1. windsurfar
    21 Posts.
    lightbulb Created with Sketch. 2
    clock Created with Sketch.
    03/05/18
    12:06
    Post #: 32856028
    Another example showing the ridiculous price we are being offered for Viralytics.

    Johnson and Johnson bought PRE-CLINICAL oncolytic Virus Company, Benevir today for $140M US up front and $900M US more in potential milestone payments.
    This is preclinical, NO HUMAN results!

    Great Human phase II data like CAVATAC  has should be worth 5-10x preclinical assets of similar type.

    Merck is getting Viralytics for $500M AUS, which is $375M US and no future revenue streams for the current shareholders.
    BOD should have done a better job!

    https://www.pharmpro.com/news/2018/05/johnson-johnson-acquire-benevir-biopharm
    VLA Price at posting: $1.72 Sentiment: Hold Disclosure: Held
    Likes Created with Sketch. 11  Upvote
    lightbulb Created with Sketch.  Great analysis
    Stroke 3 Created with Sketch. Comments Created with Sketch. Reply

  2. Top Stories

 

Featured News

ABY Adore Beauty buys up wellness brand iKOU for $25M cash
right-arrow Created with Sketch.
PDN Paladin flags up to 4.5Mlbs of uranium production in FY25 guidance
right-arrow Created with Sketch.
NEWS Tenant turnover: Reducing costs and revenue-loss
right-arrow Created with Sketch.
3DP Pointerra wins US$1.63M from US Dept of Energy to model climate change scenarios
right-arrow Created with Sketch.
SXL Southern Cross says no to buy up of Australian Community Media assets
right-arrow Created with Sketch.
RMS Ramelius boosts WA gold portfolio with stake in Spartan
right-arrow Created with Sketch.
watchlist Created with Sketch. Add VLA (ASX) to my watchlist

Currently unlisted public company.

arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.